The IL-1R1 receptor antagonist IL-1RA, a competitive inhibitor of IL-1α and IL-1β, has preclinical activity in JAK2-V617F positive MPNs and CML (82, 91). Here, IL1A is linked to chronic myelogenous leukemia, BCR-ABL1 positive.